(J Am Heart Assoc. 2016;5:e003403 doi: [10.1161/JAHA.116.003403](10.1161/JAHA.116.003403))

Introduction {#jah31538-sec-0005}
============

Dual antiplatelet therapy is a key component of management of ST‐segment elevation myocardial infarction (STEMI). Administration of a P2Y~12~ adenosine diphosphate receptor antagonist in addition to aspirin is advocated by the major international guidelines on STEMI management.[1](#jah31538-bib-0001){ref-type="ref"}, [2](#jah31538-bib-0002){ref-type="ref"} Third‐generation P2Y~12~ antagonists prasugrel and ticagrelor are recommended based on improved clinical outcomes and more potent platelet inhibition compared with the second‐generation prodrug clopidogrel. The large TRITON TIMI‐38 (n=13 608)[3](#jah31538-bib-0003){ref-type="ref"} and PLATO (n=18 624)[4](#jah31538-bib-0004){ref-type="ref"} studies demonstrated reduced medium‐term combined major adverse cardiac events (MACE) with prasugrel and ticagrelor, respectively, compared with clopidogrel in acute coronary syndromes including STEMI.[3](#jah31538-bib-0003){ref-type="ref"}, [4](#jah31538-bib-0004){ref-type="ref"}, [5](#jah31538-bib-0005){ref-type="ref"}

Mechanisms translating the more potent antiplatelet activity of prasugrel and ticagrelor into improved clinical outcomes are unclear. Cardiovascular magnetic resonance (CMR) accurately characterizes myocardial injury and function following STEMI. Late gadolinium enhancement (LGE) imaging--derived infarct size[6](#jah31538-bib-0006){ref-type="ref"} is a powerful medium‐term prognostic marker following primary percutaneous coronary intervention (PPCI). A retrospective analysis of the INFUSE‐AMI trial demonstrated a trend toward reduced 30‐day CMR infarct size and reduced 12‐month mortality with prasugrel compared with clopidogrel in anterior STEMI treated with PPCI.[7](#jah31538-bib-0007){ref-type="ref"} No other CMR data compare the effect of the third‐generation P2Y~12~ antagonists and clopidogrel after PPCI.

The primary aim of this post hoc analysis of Complete Versus Lesion‐Only PRImary PCI Trial‐CMR (CvLPRIT‐CMR) substudy was to assess whether the third‐generation P2Y~12~ antagonists prasugrel and ticagrelor were associated with reduced infarct size compared with the second‐generation P2Y~12~ antagonist clopidogrel.

Methods {#jah31538-sec-0006}
=======

Study Design {#jah31538-sec-0007}
------------

The study design and main results were published previously.[8](#jah31538-bib-0008){ref-type="ref"}, [9](#jah31538-bib-0009){ref-type="ref"} CvLPRIT‐CMR was a prespecified substudy of a multicenter, prospective, randomized, controlled, open‐label, clinical trial[8](#jah31538-bib-0008){ref-type="ref"} with blinded CMR end point analysis conducted at 7 UK centers between May 2011 and May 2014. Infarct size in patients treated with complete revascularization and in those treated with an infarct‐related artery--only strategy was not significantly different.[10](#jah31538-bib-0010){ref-type="ref"} Inclusion and exclusion criteria were the same as for the main trial with absolute contraindications to CMR imaging as an additional exclusion. The study was approved by the Trent Research Ethics Committee (reference 11/H0405/4) and conducted according to the Declaration of Helsinki. Patients provided written informed consent.

Patient Recruitment and Treatment {#jah31538-sec-0008}
---------------------------------

STEMI patients presenting within 12 hours of symptom onset were administered contemporary oral antiplatelet agents according to local guidelines. All patients received aspirin 300 mg plus 1 P2Y~12~ antagonist: (1) clopidogrel (Plavix; Sanofi), 600‐mg loading dose followed by 75‐mg maintenance; (2) prasugrel (Effient; Daiichi‐Sankyo), 60‐mg loading dose and 10 mg daily; or (3) ticagrelor (Brilique; AstraZeneca), 180‐mg loading dose and then 90 mg twice daily. Administration of the loading dose was permitted by paramedic staff before hospital arrival or in hospital on arrival at the cardiac catheterization room.

Angiographic Analysis {#jah31538-sec-0009}
---------------------

Pre‐ and post‐PPCI epicardial coronary flow was assessed using Thrombolysis In Myocardial Infarction (TIMI) scoring.[11](#jah31538-bib-0011){ref-type="ref"} Collateral flow to the infarct‐related artery (IRA) before PPCI was graded using the Rentrop system.[12](#jah31538-bib-0012){ref-type="ref"} Quantitative coronary angiography was undertaken using QAngioXA v1.0 software (Medis).

CMR Imaging {#jah31538-sec-0010}
-----------

CMR was performed before discharge, and the methods were described in detail previously.[10](#jah31538-bib-0010){ref-type="ref"} Briefly, after localizers and long‐axis cine imaging, contiguous short‐axis stacks covering the entire left ventricle were acquired with (1) T2‐weighted short τ inversion recovery to determine the ischemic area at risk (edema), (2) steady‐state free‐precession cine imaging for left ventricle volumetric analysis, and (3) LGE imaging to determine infarct size and microvascular obstruction (MVO) after administration of gadolinium contrast (0.2 mmol/kg Magnevist; Bayer).

CMR Analysis {#jah31538-sec-0011}
------------

CMR analysis was performed, as described previously, at the University of Leicester core laboratory, blinded to all clinical data including treatment allocation. If infarction was seen in \>1 coronary territory on acute CMR, this was recorded as being in the IRA territory (associated edema and/or MVO) or the non‐IRA territory, with the consensus of 3 observers (J.N.K., G.P.M., J.P.G.). Non‐IRA infarcts were also classified as likely to be acute or chronic (presence of wall thinning and no edema or MVO). Infarct size was recorded for both IRA and non‐IRA LGE, and total infarct size was the sum of all LGE.

Clinical Outcomes and Follow‐up {#jah31538-sec-0012}
-------------------------------

MACE was a composite of all‐cause mortality, recurrent MI, heart failure, and ischemia‐driven revascularization. Secondary end points included individual components of the primary end point. Safety end points comprised stroke, major bleeding, vascular access site injury, and contrast‐induced nephropathy. Data were collected by an independent clinical trials unit (Royal Brompton Hospital), and events were adjudicated by blinded clinicians.

Statistical Analysis {#jah31538-sec-0013}
--------------------

The primary CMR outcome was infarct size (expressed as percentage of left ventricular mass) on CMR, analyzed on a log‐transformed scale due to right skew. This was adjusted for known baseline predictors of infarct size (anterior myocardial infarction, diabetes mellitus, TIMI flow before PPCI, time to revascularization) and important baseline variables that significantly differed between the 2 groups (age, hypertension prevalence, timing of P2Y~12~ antagonist loading), using generalized linear models. Propensity score--based stratification (quartiles) was also performed to adjust for the imbalance of baseline covariates between the 2 groups.[13](#jah31538-bib-0013){ref-type="ref"} Starting with the noted baseline covariates, the propensity score model was built based on a backward selection process and the assessment of balance between the 2 groups. Normally distributed variables were expressed as mean±SD and compared using Student *t* tests. Nonnormally distributed data were expressed as median (quartiles 1--3) and analyzed using Mann--Whitney testing. Categorical variables were compared using chi‐square testing. Clinical outcomes were assessed using time‐to--first event survival analysis (log‐rank test with right censoring), and Cox proportional hazards models were fitted to estimate hazard ratios and 95% CIs for treatment comparisons.

Results {#jah31538-sec-0014}
=======

Baseline Characteristics {#jah31538-sec-0015}
------------------------

Patients receiving clopidogrel were slightly older (67.8±12.3 years versus 61.5±9.6 years, *P*\<0.001) and had a higher prevalence of hypertension compared with those receiving prasugrel or ticagrelor. Other baseline characteristics and comorbidities were closely matched in patients receiving clopidogrel and the third‐generation P2Y~12~ antagonist agents and were similar to those in the overall CvLPRIT study cohort (Table [1](#jah31538-tbl-0001){ref-type="table-wrap"}).

###### 

Baseline Characteristics of the Main CvLPRIT Study Population and Patients Receiving Clopidogrel and the Third‐Generation P2Y~12~ Antagonist Antiplatelet Agents (Prasugrel, Ticagrelor)

  Variable                                            Main CvLPRIT (n=296)   Newer P2Y~12~ Antagonists (n=133)   Clopidogrel (n=70)   *P* Value
  --------------------------------------------------- ---------------------- ----------------------------------- -------------------- -----------
  Age, y                                              64.9±11.6              61.5±9.6                            67.8±12.3            \<0.001
  Male sex                                            240/296 (81.1)         114/133 (85.7)                      56/70 (80.0)         0.29
  Body mass index, kg/m^2^                            27.3 (24.4--30.2)      27.5 (24.8--29.9)                   27.6 (24.3--30.5)    0.61
  Systolic blood pressure, mm Hg                      137.6±27.1             133.5 (116--156)                    137 (120--153)       0.86
  Anterior infarct                                    106 (35.6)             46/133 (34.6)                       26/70 (37.1)         0.72
  Estimated glomerular filtration rate, mL/min/1.73   95.74±34.7             100.0±29.0                          87.7±37.3            0.013
  Hypertension                                        105/287 (36.6)         39/133 (29.3)                       34/70 (48.6)         0.007
  Hypercholesterolemia                                75/287 (26.1)          36/133 (27.1)                       20/70 (28.6)         0.82
  Diabetes mellitus                                   39/287 (13.6)          19/133 (14.3)                       9/70 (12.9)          0.78
  Current smoker                                      87/285 (30.5)          46/133 (34.6)                       18/70 (25.7)         0.20
  Previous myocardial infarction                      12/287 (4.2)           4/133 (3.0)                         4/70 (5.7)           0.35
  Previous percutaneous coronary intervention         9/287 (3.1)            4/133 (3.0)                         3/70 (4.3)           0.64
  Antianginal medication, beta blockers or nitrates   54/287 (18.8)          18/132 (13.6)                       15/70 (21.4)         0.16
  Killip class II to III                              24/286 (8.4)           11/133 (8.3)                        5/70 (7.1)           0.78

Data expressed as mean±SD, median (quartiles 1--3), or frequency (percentage) of patients, as appropriate. *P* values compare the treatment groups (clopidogrel vs third‐generation P2Y~12~ antiplatelet agents).

CvLPRIT indicates Complete Versus Lesion‐Only PRImary PCI Trial.

Baseline characteristics for patients receiving the 3 individual P2Y~12~ antagonists are shown in Table S1. Patients receiving clopidogrel were older than those receiving prasugrel because age \>75 years is a contraindication to prasugrel therapy.

Angiographic and PCI Details {#jah31538-sec-0016}
----------------------------

Details of angiography and PCI are shown in Table [2](#jah31538-tbl-0002){ref-type="table-wrap"}. There was a trend toward longer median time from symptom onset to revascularization in patients receiving clopidogrel (*P*=0.05). Prehospital P2Y~12~ antagonist administration was more common in patients receiving clopidogrel compared with those receiving prasugrel or ticagrelor (*P*=0.001). There was a higher prevalence of visible thrombus (*P*=0.041) and thrombectomy catheter use (*P*=0.034) in patients receiving clopidogrel. Complexity of coronary artery disease, prevalence of well‐collateralized IRA territory, use of glycoprotein IIb/IIIa inhibitors and bivalirudin, and performance of multivessel PCI were similar in patients receiving clopidogrel and prasugrel or ticagrelor.

###### 

Periprocedural Details in Patients Receiving Clopidogrel and the Third‐Generation P2Y~12~ Antiplatelet Agents (Prasugrel, Ticagrelor)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                             Newer P2Y~12~ Antagonists (n=133)   Clopidogrel (n=70)   *P* Value
  ------------------------------------------------------------------------------------ ----------------------------------- -------------------- -----------
  Radial access                                                                        106/132 (80.3)                      57/70 (81.4)         0.85

  Time from symptoms to PCI (time to revascularization), min                           177 (125--240)                      234 (144--320)       0.051

  Glycoprotein IIb/IIIa inhibitors                                                     45/131 (34.4)                       25/70 (35.7)         0.85

  Bivalirudin                                                                          59/122 (48.4)                       36/64 (56.2)         0.31

  Visible thrombus                                                                     79/133 (59.8)                       52/70 (74.3)         0.041

  Thrombectomy catheter                                                                89/132 (67.4)                       57/70 (81.4)         0.034

  Contrast dose, mL                                                                    220 (180--300)                      250 (180--367.5)     0.13

  Screening time, min                                                                  12 (8--19)                          13 (8.25--18.75)     0.37

  Procedure length, min                                                                46 (31--70)                         56.5 (40--74.3)      0.041

  Quantitative coronary angiography, vessels with ≥75% stenosis                        1.48±0.6                            1.53±0.6             0.60

  Quantitative coronary angiography, lesions ≥75% stenosis                             1.59±0.7                            1.66±0.7             0.51

  Quantitative coronary angiography, stenosis in non--infarct‐related artery lesions   72.0±12.3                           70.8±10.6            0.49

  SYNTAX score (total)                                                                 17.5 (13--22.5)                     18 (14--23.5)        0.99

  Left anterior descending infarct‐related artery                                      48/133 (36.1)                       24/70 (34.3)         0.80

  Left circumflex infarct‐related artery                                               26/133 (19.5)                       12/70 (17.1)         0.68

  Right coronary infarct‐related artery                                                59/133 (44.4)                       33/70 (47.1)         0.71

  Rentrop grade                                                                        0 (0--1)                            0 (0--1)             0.51

  Rentrop grade 2--3 before PCI                                                        6/133 (4.5)                         7/70 (10.0)          0.13

  Thrombolysis In Myocardial Infarction grade before PCI                               0 (0--1), 0.58±1.0                  0 (0--0), 0.36±0.8   0.95

  Thrombolysis In Myocardial Infarction grade after PCI                                3 (3--3), 2.77±0.5                  3 (3--3), 2.92±0.4   0.39

  Infarct‐related artery, no reflow                                                    6/133 (4.5)                         4/70 (5.7)           0.71

  Total number of stents                                                               2 (1--3)\                           2 (1--3)\            0.54
                                                                                       2.2±1.3                             2.1±1.3              

  Drug‐eluting stent use                                                               127/133 (95.5)                      66/70 (94.3)         0.71

  Multivessel PCI (complete revascularization)                                         64/133 (48.1)                       34/70 (48.6)         0.95

  Peak CK, IU/L                                                                        992 (550--1631)                     1214 (649--1960)     0.35

  Aspirin                                                                              132/133 (99.2)                      70/70 (100)          0.47

  Timing of aspirin administration                                                                                                              

  Prehospital                                                                          113/124 (91.1)                      56/67 (83.6)         0.12

  In‐hospital before angiogram                                                         11/124 (8.9)                        11/67 (16.4)         

  P2Y~12~ antagonist administration                                                                                                             

  Prehospital                                                                          11/132 (8.3)                        17/64 (26.6)         0.001

  In‐hospital before angiogram                                                         121/132 (91.7)                      47/64 (73.4)         

  Discharge medication                                                                                                                          

  Beta blocker                                                                         125/133 (94.0)                      65/70 (92.9)         0.76

  Angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker              126/133 (94.7)                      70/70 (100)          0.06

  Lipid‐lowering therapy                                                               132/133 (99.3)                      70/70 (100)          0.47

  Loop diuretic                                                                        14/133 (10.5)                       8/70 (11.3)          0.86

  Aldosterone inhibitor                                                                7/133 (5.3)                         3/70 (4.3)           0.76
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

Data expressed as mean±SD, median (quartiles 1--3), or frequency (percentage) of patients, as appropriate. *P* values compare the treatment groups (clopidogrel vs third‐generation P2Y~12~ antiplatelet agents). CK indicates creatine kinase; PCI, percutaneous coronary intervention; SYNTAX, SYnergy between PCI with TAXus and cardiac surgery.

Approximately a quarter of patients receiving clopidogrel and ticagrelor were administered loading doses before arriving at the hospital; however, only 7% of prasugrel patients were loaded before arrival (Table S1).

CMR Outcomes {#jah31538-sec-0017}
------------

CMR results are displayed in Table [3](#jah31538-tbl-0003){ref-type="table-wrap"}. CMR was undertaken at a median of 2.9 days after PPCI in both groups. Left ventricular volumes were similar in the 2 groups, and ejection fraction was not significantly different. Overall, 94% of patients in each group demonstrated infarct on LGE. There was a similar prevalence of multiple infarcts in patients receiving clopidogrel and prasugrel or ticagrelor. The primary end point of median total infarct size was significantly larger in patients receiving clopidogrel (16.1% \[quartiles 1--3, 10.5--27.7%\] versus 12.1% \[quartiles 1--3, 4.8--20.7%\]) of left ventricular mass, *P*=0.013). After adjustment for key covariates, infarct size remained larger in patients receiving clopidogrel, using both generalized linear models (*P*=0.048) and propensity score analysis (*P*=0.025). When chronic infarcts were excluded, median total acute infarct size (*P*=0.034) and median extent of the main IRA‐related infarct (*P*=0.033) were significantly greater in the clopidogrel group ([Figure](#jah31538-fig-0001){ref-type="fig"}).

###### 

Acute Cardiovascular Magnetic Resonance Data in Patients Receiving Clopidogrel and the Third‐Generation P2Y~12~ Antiplatelet Agents (Prasugrel, Ticagrelor)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                                                  Newer P2Y~12~ (Antagonists ((n=133)   Clopidogrel (n=70)   *P* Value
  ------------------------------------------------------------------------- ------------------------------------- -------------------- -----------------------------------------------
  Acute cardiovascular magnetic resonance                                                                                              

  Total infarct size, % LVM                                                 12.1 (4.8--20.7)                      16.1 (10.5--27.7)    0.013\
                                                                                                                                       0.048[a](#jah31538-note-0007){ref-type="fn"}\
                                                                                                                                       0.025[b](#jah31538-note-0008){ref-type="fn"}

  Time to acute cardiovascular magnetic resonance, day                      2.9 (1.9--4.1)                        2.9 (2.0--3.8)       0.33

  Infarct present on late gadolinium enhancement                            124/133 (93.6)                        66/70 (94.3)         0.77

  Patients with \>1 infarct                                                 22/133 (16.5)                         11/70 (15.7)         0.88

  Patients with \>1 acute infarct                                           14/133 (10.5)                         8/70 (11.4)          0.84

  Infarct‐related artery infarct size (main infarct), % LVM                 10.0 (4.4--18.9)                      15.6 (9.8--26.3)     0.002\
                                                                                                                                       0.033[a](#jah31538-note-0007){ref-type="fn"}\
                                                                                                                                       0.011[b](#jah31538-note-0008){ref-type="fn"}

  Non--infarct‐related artery infarct size (total), % LVM                   0.00 (0.00--0.00)                     0.00 (0.00--0.00)    0.47\
                                                                                                                                       0.86[a](#jah31538-note-0007){ref-type="fn"}

  Total infarct size (% LVM) of acute infarcts                              10.6 (4.4--19.0)                      16.0 (10.4--27.6)    0.013\
                                                                                                                                       0.034[a](#jah31538-note-0007){ref-type="fn"}\
                                                                                                                                       0.013[b](#jah31538-note-0008){ref-type="fn"}

  Area at risk, % LVM[c](#jah31538-note-0009){ref-type="fn"}                32.8±12.9                             36.8±11.4            0.07

  Myocardial salvage index, %                                               63.3 (42.9--82.6)                     46.2 (24.7--70.2)    0.06\
                                                                                                                                       0.12[a](#jah31538-note-0007){ref-type="fn"}

  Microvascular obstruction present                                         65/133 (48.9)                         46/70 (65.7)         0.022

  Microvascular obstruction, % LVM[a](#jah31538-note-0007){ref-type="fn"}   0.0 (0--1.1)                          0.25 (0--2.3)        0.06\
                                                                                                                                       0.49[a](#jah31538-note-0007){ref-type="fn"}

  Left ventricular mass index, g/m^2^                                       51.7 (45.6--60.6)                     52.6 (45.9--60.0)    0.99

  Left ventricular end‐diastolic volume index, mL/m^2^                      89.5 (80.6--102.0)                    91.1 (80.5--101.2)   0.62

  Left ventricular end‐systolic volume index, mL/m^2^                       46.4 (37.9--60.6)                     48.9 (41.6--59.3)    0.64

  Left ventricular ejection fraction, %                                     46.0±10.5                             44.4±7.8             0.20
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data expressed as mean±SD, median (quartiles 1--3), or frequency (percentage) of patients, as appropriate. LVM indicates left ventricular mass.

*P* value adjusted for known baseline predictors of infarct size (anterior myocardial infarction, time to revascularization, diabetes, Thrombolysis In Myocardial Infarction flow before primary percutaneous coronary intervention) and important baseline variables significantly differing between the groups (age, hypertension prevalence, timing of P2Y~12~ antagonist loading) using regression analysis.

*P* value based on propensity score analysis with the propensity scores estimating from age, presence of hypertension, time to revascularization, and timing of P2Y~12~ antagonist loading.

Analyzable edema imaging available in ≈75% of patients in both groups.

![Median acute IS in patients receiving clopidogrel and the newer (third‐generation P2Y~12~ antagonist) antiplatelet agents prasugrel (P) and ticagrelor (T). IRA indicates infarct‐related artery; IS, infarct size; LV, left ventricular.](JAH3-5-e003403-g001){#jah31538-fig-0001}

The prevalence of microvascular obstruction was higher in patients receiving clopidogrel (65.7% versus 48.9%, *P*=0.022). In 52 patients (26%), area at risk could not be reliably quantified because no artifact but no edema was discernable (n=33), imaging was not performed because of arrhythmia or suboptimal breath holding (n=14), or severe artifact was present (n=5). There was a trend toward lower myocardial salvage index in the clopidogrel group (*P*=0.12).

CMR outcomes on an individual P2Y~12~ antagonist basis are shown in Table S2. Total infarct size, IRA‐related infarct size, and total acute infarct size were similar in patients receiving prasugrel and ticagrelor but were significantly smaller with both of these agents compared with clopidogrel.

Clinical Outcomes {#jah31538-sec-0018}
-----------------

Discharge medication was similar between the groups (Table [2](#jah31538-tbl-0002){ref-type="table-wrap"}). Median follow‐up was 368 days (clopidogrel group 355 days, prasugrel/ticagrelor group 372 days; *P*=0.05) (Table [4](#jah31538-tbl-0004){ref-type="table-wrap"}). Length of inpatient stay was longer (4.4±3.6 versus 3.3±2.0, *P*=0.017) in patients receiving clopidogrel. There was a nonsignificant trend toward reduced overall 12‐month MACE (17.1% versus 10.5%, *P*=0.18) driven mainly by a reduced incidence of heart failure (*P*=0.04). There was no difference in the incidence of safety end points between the groups.

###### 

Clinical Outcomes in Patients Receiving Clopidogrel and the Third‐Generation P2Y~12~ Antiplatelet Agents (Prasugrel, Ticagrelor)

  Variable                                             Newer P2Y~12~ Antagonists (n=133)   Clopidogrel (n=70)   Hazard Ratio (95% CI)   *P* Value
  ---------------------------------------------------- ----------------------------------- -------------------- ----------------------- -----------
  12‐month follow‐up                                                                                                                    
  Major adverse cardiac events                         14/133 (10.5)                       12/70 (17.1)         0.59 (0.27--1.3)        0.18
  All‐cause mortality                                  1/133 (0.8)                         1/70 (1.4)           0.52 (0.03--8.5)        0.64
  Recurrent myocardial infarction                      3/133 (2.3)                         0/70 (0.0)           ---                     0.21
  Type 1                                               2/133 (1.6)                         0/70 (0.0)           ---                     0.43
  Type 4b                                              1/133 (0.8)                         0/70 (0.0)           ---                     0.66
  Heart failure                                        2/133 (1.5)                         5/70 (7.1)           0.20 (0.04--1.0)        0.04
  Revascularization                                    8/133 (6.0)                         6/70 (8.6)           0.66 (0.23--1.9)        0.45
  Safety end points                                                                                                                     
  Contrast nephropathy                                 1/133 (0.8)                         0/70 (0.0)           ---                     0.47
  Vascular access injury                               0/133 (0.0)                         0/70 (0.0)           ---                     1.00
  Cerebrovascular accident/transient ischemic attack   1/133 (0.8)                         1/70 (1.4)           0.52 (0.03--8.5)        0.64
  Major bleed                                          2/133 (1.6)                         2/70 (2.9)           0.52 (0.07--3.8)        0.51

Data expressed as frequency (percentage) of patients.

On an individual P2Y~12~ antagonist basis, there was a trend toward reduced 12‐month MACE with both prasugrel and ticagrelor compared with clopidogrel (Tables S3--S5).

Discussion {#jah31538-sec-0019}
==========

This post hoc analysis of the CvLPRIT‐CMR substudy participants is, to our knowledge, the first imaging‐based study assessing myocardial and microvascular injury associated with the second‐generation P2Y~12~ antagonist clopidogrel and the third‐generation P2Y~12~ antagonists prasugrel and ticagrelor in STEMI. P2Y~12~ antagonism with prasugrel and ticagrelor was associated with reduced total and IRA‐associated infarct size and reduced microvascular obstruction incidence on CMR LGE imaging after PPCI. This post hoc analysis was nonrandomized; therefore, there were baseline differences, with higher age, prevalence of hypertension, and prehospital administration of P2Y~12~ antagonists, and a trend toward increased symptom time to reperfusion in patients receiving clopidogrel. Despite adjusting for these variables and known baseline predictors of infarct size, the results may still suffer from biases and thus should be considered as hypothesis generating but warranting investigation in larger randomized studies.

Infarct Size and MVO {#jah31538-sec-0020}
--------------------

The greater total and IRA‐related infarct size and incidence of MVO in patients receiving clopidogrel may be influenced by baseline differences, in particular, the trend toward longer time to revascularization, which is a determinant of CMR infarct size[14](#jah31538-bib-0014){ref-type="ref"}, [15](#jah31538-bib-0015){ref-type="ref"} and prognosis in STEMI.[16](#jah31538-bib-0016){ref-type="ref"} Importantly, the differences in infarct size and MVO incidence persisted after correction for baseline differences in patient characteristics and their known predictors. It is unlikely that patients receiving clopidogrel had larger infarcts because the proportion having anterior STEMI and Killip class were similar in the groups, and there was greater prehospital clopidogrel administration.[17](#jah31538-bib-0017){ref-type="ref"} Although the prevalence of visible thrombus was higher in the clopidogrel group, TIMI flow grade before PPCI and technical success at PPCI were similar, and the former was adjusted to correct for higher thrombus burden. In addition, all patients receiving clopidogrel had the larger 600‐mg loading dose, which, in a previous retrospective study in 198 patients, was associated with reduced CMR‐derived infarct size and MVO and increased myocardial salvage after PPCI.[18](#jah31538-bib-0018){ref-type="ref"} The higher infarct size and MVO incidence occurred despite a weak trend toward greater degree of IRA collateralization, which can attenuate infarct size and MVO,[19](#jah31538-bib-0019){ref-type="ref"}, [20](#jah31538-bib-0020){ref-type="ref"} in the patients receiving clopidogrel.

Our results are consistent with the only imaging‐based study comparing second‐ and third‐generation P2Y~12~ antagonists. Brener et al[7](#jah31538-bib-0007){ref-type="ref"} demonstrated a strong trend toward reduced total infarct size measured on CMR at 30 days with prasugrel compared with clopidogrel in acute anterior STEMI treated with PPCI (16.4% versus 17.6% left ventricular mass, *P*=0.06). Our results are also supported by the findings of Nanhwan et al,[21](#jah31538-bib-0021){ref-type="ref"} who demonstrated that ticagrelor but not clopidogrel reduced infarct size in rats measured histologically.

The lower myocardial and microvascular injury observed in patients receiving prasugrel and ticagrelor in our study may be affected by the faster (peak effect after loading dose at 2 hours for ticagrelor, 4 hours for prasugrel, and 6 hours after clopidogrel)[22](#jah31538-bib-0022){ref-type="ref"}, [23](#jah31538-bib-0023){ref-type="ref"}, [24](#jah31538-bib-0024){ref-type="ref"} and more potent[23](#jah31538-bib-0023){ref-type="ref"}, [25](#jah31538-bib-0025){ref-type="ref"} antiplatelet activity of these drugs compared with the prodrug clopidogrel. Indeed, clopidogrel typically achieves a maximum of only 50% platelet inhibition in combination with aspirin in acute coronary syndromes compared with ≈90% with prasugrel and aspirin[26](#jah31538-bib-0026){ref-type="ref"} and ≈94% with ticagrelor and aspirin.[27](#jah31538-bib-0027){ref-type="ref"} This remains the case even when the larger 600‐mg clopidogrel loading dose is administered.[22](#jah31538-bib-0022){ref-type="ref"}, [25](#jah31538-bib-0025){ref-type="ref"} In addition, the prodrug forms only 15% of the clopidogrel metabolite, with 85% de‐esterised into an inactive carboxylic acid.[28](#jah31538-bib-0028){ref-type="ref"} Prasugrel has also been shown to be associated with lower drug resistance than clopidogrel. Brandt et al demonstrated that 42% of clopidogrel‐treated patients were associated with \<20% platelet noninhibition at 4 hours after administration compared with 0% of prasugrel‐treated patients.[25](#jah31538-bib-0025){ref-type="ref"} This may be related to the fact that prasugrel and ticagrelor metabolism have been shown not to be affected by cytochrome P450 polymorphisms.[28](#jah31538-bib-0028){ref-type="ref"}, [29](#jah31538-bib-0029){ref-type="ref"} It is interesting to speculate that prasugrel[30](#jah31538-bib-0030){ref-type="ref"} and ticagrelor,[21](#jah31538-bib-0021){ref-type="ref"}, [31](#jah31538-bib-0031){ref-type="ref"} which have anti‐inflammatory and antiapoptotic activity, may protect against reperfusion injury, which is known to contribute to CMR‐derived infarct size, MVO, and intramyocardial hemorrhage.[32](#jah31538-bib-0032){ref-type="ref"}

Clinical Outcomes {#jah31538-sec-0021}
-----------------

This study was not powered to detect differences in clinical outcomes; however, we saw reduced incidence of heart failure (*P*=0.04), with a weak nonsignificant trend toward reduced combined 12‐month MACE (17.1% versus 10.5%, *P*=0.18) with the newer agents versus clopidogrel. These findings are consistent with previous studies demonstrating improved medium‐term clinical outcomes with ticagrelor[4](#jah31538-bib-0004){ref-type="ref"} and prasugrel[3](#jah31538-bib-0003){ref-type="ref"}, [7](#jah31538-bib-0007){ref-type="ref"}, [33](#jah31538-bib-0033){ref-type="ref"}, [34](#jah31538-bib-0034){ref-type="ref"} in STEMI, in particular, the work of Brener et al[7](#jah31538-bib-0007){ref-type="ref"} demonstrating reduced infarct size, mortality, and heart failure at 12‐month follow‐up with prasugrel compared with clopidogrel. The reduction in heart failure incidence in our study could caused by the lower infarct size.

Limitations {#jah31538-sec-0022}
-----------

In this post hoc analysis, patients were not randomized to a particular P2Y~12~ antagonist. The differences in baseline characteristics, in particular, symptom time to reperfusion, may influence the observed differences in infarct size and MVO incidence between the patients; however, our findings persisted after correction for baseline differences and important covariates. The study was not powered to detect differences in clinical outcomes. Patients who died early or who were unstable after PPCI were unlikely to have participated in the CMR study, which may have underestimated hard end points. We combined patients receiving prasugrel and ticagrelor into a single group in the main analysis of this study because of the relatively small number of patients receiving ticagrelor (31 of 203 \[15%\]) and because patients receiving these P2Y~12~ antagonists agents were very similar at baseline and had similar infarct sizes.

Conclusions {#jah31538-sec-0023}
===========

In this post hoc analysis of the CvLPRIT study, patients with multivessel coronary disease undergoing PPCI and receiving prasugrel or ticagrelor had smaller total infarct size and reduced incidence of MVO on CMR imaging compared with those receiving clopidogrel. These findings persisted after correction for baseline differences in patient characteristics and important covariates. These findings may help explain the improved clinical outcomes with the use of third‐generation antiplatelet agents compared with clopidogrel.
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